organization · Reporting owner
MERCK SERONO S.A.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECIGEN, INC.XON · Entity 4356 | 10% owner | December 28, 2018 | January 22, 2019 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | 10% owner | May 13, 2021 | May 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECIGEN, INC.
Report date December 28, 2018 · Filed January 22, 2019
Jointly reported with Ares Trading S.A., Merck KGaA
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,640,119 |
Reported balance
Holding disclosure · report date 2018-12-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,640,119 F1: In addition to the securities reported herein, Ares Trading S.A. holds a Convertible Note in the original principal amount of $25,000,000 which is convertible at any time into Common Stock of the Issuer, subject to limited exceptions, at a conversion price equal to (a) the volume weighted-average price per share of the Common Stock on the Nasdaq Stock Market for the consecutive ten trading days immediately prior to the conversion date as reported by Bloomberg, L.P. or (b) if converted in connection with a qualified public offering by the Issuer, the lowest price per share paid by a purchaser in such qualified public offering. The Convertible Note and shares of Issuer Common Stock issuable thereunder, which are not reported as beneficially owned herein pursuant to Rule 16a-1(c)(6) promulgated under the Securities Exchange Act of 1934, are more fully described in the Schedule 13G filed by the Reporting Persons on January 7, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: In addition to the securities reported herein, Ares Trading S.A. holds a Convertible Note in the original principal amount of $25,000,000 which is convertible at any time into Common Stock of the Issuer, subject to limited exceptions, at a conversion price equal to (a) the volume weighted-average price per share of the Common Stock on the Nasdaq Stock Market for the consecutive ten trading days immediately prior to the conversion date as reported by Bloomberg, L.P. or (b) if converted in connection with a qualified public offering by the Issuer, the lowest price per share paid by a purchaser in such qualified public offering. The Convertible Note and shares of Issuer Common Stock issuable thereunder, which are not reported as beneficially owned herein pursuant to Rule 16a-1(c)(6) promulgated under the Securities Exchange Act of 1934, are more fully described in the Schedule 13G filed by the Reporting Persons on January 7, 2019.
Vera Therapeutics, Inc.
Report date May 13, 2021 · Filed May 14, 2021
Jointly reported with Ares Trading S.A., Merck KGaA
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-05-13 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Series C Preferred Stock is convertible into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and has no expiration date. Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Class A Common Stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series C Preferred Stock is convertible into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and has no expiration date. Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Class A Common Stock of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
No transactions match
Try broader filters. Historical coverage is still being backfilled.
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.